Provided by Tiger Trade Technology Pte. Ltd.

Immatics N.V.

9.92
+0.01500.15%
Volume:70.37K
Turnover:713.11K
Market Cap:1.33B
PE:-8.83
High:10.25
Open:9.97
Low:9.89
Close:9.90
52wk High:12.41
52wk Low:3.30
Shares:134.06M
Float Shares:62.52M
Volume Ratio:0.18
T/O Rate:0.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1224
EPS(LYR):0.1449
ROE:-30.03%
ROA:-16.22%
PB:2.69
PE(LYR):68.41

Loading ...

Immatics’ treatment of Stage II and higher CM granted FDA orphan designation

TIPRANKS
·
Feb 11

Biotech Sector Poised for Growth Driven by Trial Data, Pharma Deals, BofA Says

MT Newswires Live
·
Jan 07

BofA Adjusts Price Target on Immatics to $17 From $14, Maintains Buy Rating

MT Newswires Live
·
Jan 06

Immatics Reports Promising Early Results for IMA203CD8 PRAME Cell Therapy in Phase 1a Trial

Reuters
·
Dec 11, 2025

Immatics (NasdaqCM:IMTX) Valuation Check After Dilutive Follow-On Equity Offering and Sharp One-Day Share Price Drop

Simply Wall St.
·
Dec 08, 2025

How Investors Are Reacting To Immatics (IMTX) $125 Million Follow-On Equity Offering

Simply Wall St.
·
Dec 07, 2025

Immatics Down Nearly 15%, on Pace for Largest Percent Decrease Since October 2024 -- Data Talk

Dow Jones
·
Dec 06, 2025

Immatics Shares Decline on $125 Million Public Offering

Dow Jones
·
Dec 05, 2025

Immatics Plans $125 Million Stock Offering

MT Newswires Live
·
Dec 05, 2025

Immatics Announces $125 Million Underwritten Offering

GlobeNewswire
·
Dec 05, 2025

Immatics N.V. Reports Q3 2025 Financial Results and Progress

TIPRANKS
·
Nov 26, 2025

Immatics Is Maintained at Buy by Chardan Capital

Dow Jones
·
Nov 25, 2025

PRAME Oncology Advances Could Be a Game Changer for Immatics (IMTX)

Simply Wall St.
·
Nov 21, 2025

Stock Track | Immatics Soars 5.07% as Analysts Maintain Buy Ratings and Raise Price Targets

Stock Track
·
Nov 19, 2025

Stock Track | Immatics (IMTX) Soars 5% as Analysts Reaffirm Buy Ratings and Raise Price Targets

Stock Track
·
Nov 19, 2025

Immatics Is Maintained at Buy by Guggenheim

Dow Jones
·
Nov 18, 2025

Immatics price target raised to $19 from $16 at Guggenheim

TIPRANKS
·
Nov 18, 2025

Immatics Nv : Leerink Partners Raises Target Price to $16 From $15

THOMSON REUTERS
·
Nov 17, 2025

Sector Update: Health Care Stocks Mixed Pre-Bell Monday

MT Newswires Live
·
Nov 17, 2025

Immatics Q3 Net Loss Widens, Revenue Drops

MT Newswires Live
·
Nov 17, 2025